Open-Label Extension of Voxelotor

Summary

Open-label extension study of voxelotor for participants with Sickle Cell Disease who have participated in voxelotor clinical trials.

Timeline

Start

2019-11-18

Primary completion

2024-11-01

Completion

2024-11-01

Outcome

Outcome not reported

Stopped: “Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment.”

Drugs

Indications